Guangzhou Aiqixi New Drug Research

Guangzhou Aiqixi New Drug Research is a clinical-stage biotechnology company headquartered in Guangzhou, China, specializing in the discovery and development of novel small molecule drugs. The company's research efforts are primarily focused on oncology, metabolic diseases, and inflammatory conditions. Its lead candidate, AC-001, is a third-generation EGFR inhibitor designed to treat non-small cell lung cancer. Aiqixi leverages its internal R&D capabilities to advance a diverse pipeline of kinase inhibitors and metabolic modulators. The company aims to provide effective and affordable therapeutic options for patients with significant unmet medical needs. It maintains a strong focus on precision medicine and targeted therapies within the Chinese pharmaceutical market.